Wednesday, November 18, 2026

Celltrion Grows Its Biosimilar Business... Targets 7 Trillion Won in Revenue Next Year

Input
2026-11-18 07:52:31
Updated
2026-11-18 07:52:31

[Financial News] Hana Securities initiated coverage of Celltrion, assigning it a Buy (BUY) rating and a target price of 310,000 won. Despite increased volatility in the stock market recently, the firm expects Celltrion to sustain its growth, driven by expanded sales of new biosimilar products and strong direct-sales performance in the United States.
On the 18th, Hana Securities estimated Celltrion’s consolidated revenue this year at 5.8478 trillion won and operating profit at 1.8939 trillion won. These figures represent year-on-year increases of 40.5% and 62.1%, respectively. The firm also forecast that the results would exceed the company’s annual guidance of 5.3 trillion won in revenue and 1.8 trillion won in operating profit.
Kim Sun-ah, an analyst at Hana Securities, said, “The five newly launched products are driving revenue growth, and operating margins are also improving as these products account for a growing share of revenue.” She explained that the new products are driving both growth and improved profitability on top of the stable revenue base provided by existing products.
The earnings growth trend has already been evident since the third quarter. Celltrion’s consolidated revenue in the third quarter was 1.5755 trillion won, up 53% from a year earlier and 13% from the previous quarter. Operating profit rose to 525.3 billion won, up 74% year on year and 16% quarter on quarter. The operating margin was 33%.
The contribution from newly launched products has been particularly notable. According to Hana Securities, five products—Steqeyma, OMLYCLO, Stoboclo and Osenvelt, AVTOZMA, and Idenselt—boosted revenue by 356.8 billion won year on year in the second quarter. Given that revenue from existing products increased by 24.2 billion won, the new products played a substantial role in overall growth.
Direct-sales performance in the U.S. market was also cited as a key investment point. Since beginning direct sales in North America in the second quarter of 2023, Celltrion has strengthened its local sales capabilities through contracts with pharmacy benefit managers (PBMs), the establishment of distribution networks, and its pricing competitiveness. Market penetration has also accelerated as the company has rolled out new products sequentially since 2024.
U.S. prescriptions for ZYMFENTRA, the company’s flagship product, increased 12.8% quarter on quarter in the third quarter of this year. With the prescribing base for new products expanding and existing products maintaining or growing their market shares, analysts say Celltrion’s U.S. direct-sales system is beginning to deliver results in earnest.
Changes in the U.S. policy environment are also fueling expectations for medium- to long-term growth. Kim forecast that, following this year’s U.S. midterm elections, discussions on expanding Medicaid eligibility and strengthening healthcare and welfare support—initiatives pursued by the Democratic Party—would be a major market focus next year. The reasoning is that, with public finances constrained, expanding healthcare and welfare coverage will require greater use of relatively cost-effective biosimilars.
Kim explained, “With a limited budget, there will be no choice but to encourage the use of biosimilars to expand welfare coverage, and companies with high biosimilar sales in the U.S. are bound to attract the market’s attention.”
She added, “If the company can demonstrate through its quarterly results that demand for its biosimilars is high in the U.S., its share price could break through its previous high and rise rapidly.”
The contract development and manufacturing organization (CDMO) business was also presented as a new growth engine. Celltrion secured a local manufacturing base by acquiring a production facility in Branchburg, New Jersey, and has begun generating contract manufacturing (CMO) revenue from Eli Lilly and Company this year. However, because of a structure in which this is offset by amortization expenses related to the acquisition, its contribution to earnings is expected to remain limited through 2028, with a more substantial contribution possible from 2029.
Kim projected revenue of 7.0699 trillion won and operating profit of 2.3786 trillion won for next year. The target price of 310,000 won was calculated by applying a discount rate to next year’s earnings before interest, taxes, depreciation, and amortization (EBITDA), then factoring in a target EV/EBITDA multiple of 29. This represents potential upside of about 45.5% from the previous day’s closing price of 213,000 won.

[email protected] Kang Jung-mo Reporter